This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Research Reports for Eli Lilly, T-Mobile & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
EXCPositive Net Change HPQNegative Net Change LLYPositive Net Change BHPPositive Net Change AIGPositive Net Change TMUSPositive Net Change
communications industrial-products pharmaceuticals
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
by Zacks Equity Research
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
NVSPositive Net Change RHHBYPositive Net Change KRYSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
GILDPositive Net Change ABBVPositive Net Change KRYSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
RAREPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
REGNPositive Net Change SNYPositive Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
by Kinjel Shah
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
SNYPositive Net Change AZNPositive Net Change RHHBYPositive Net Change JNJPositive Net Change MRKPositive Net Change
pharmaceuticals
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
by Zacks Equity Research
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
JNJPositive Net Change MRKPositive Net Change HRTXPositive Net Change BVSNegative Net Change
pharmaceuticals
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
BHVNNegative Net Change ENTXNegative Net Change IMVTNegative Net Change ALXONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm
by Zacks Equity Research
NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm are part of the Zacks top Analyst Blog.
QCOMNegative Net Change CEGNegative Net Change MUNegative Net Change NVDANegative Net Change MRNANegative Net Change
communications computers oil-energy pharmaceuticals semiconductor
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
AZNPositive Net Change RHHBYPositive Net Change PFEPositive Net Change KRYSNegative Net Change
pharmaceuticals
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
by Zacks Equity Research
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
AZNPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
by Zacks Equity Research
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
BMYPositive Net Change PRTAPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
by Zacks Equity Research
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
REGNPositive Net Change SNYPositive Net Change JNJPositive Net Change BVSNegative Net Change
pharmaceuticals
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
by Zacks Equity Research
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change CADLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
by Zacks Equity Research
Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.
MRKPositive Net Change MRNANegative Net Change HRTXPositive Net Change ARQTNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
HRTXPositive Net Change PMVPPositive Net Change BVSNegative Net Change ACRVPositive Net Change
pharmaceuticals
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
NVOPositive Net Change AMGNPositive Net Change BMIPositive Net Change MUNegative Net Change TSCOPositive Net Change SEPositive Net Change EVERNegative Net Change KALUNegative Net Change MTDPositive Net Change PLMRNegative Net Change AYRWFPositive Net Change
pharmaceuticals semiconductor transportation
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
by Zacks Equity Research
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
APLSNegative Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
by Zacks Equity Research
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
NVSPositive Net Change KRYSNegative Net Change MORPositive Net Change ALXONegative Net Change
biotechnology biotechs pharmaceuticals
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
SNYPositive Net Change BMYPositive Net Change MRNSNegative Net Change KRYSNegative Net Change
pharmaceuticals
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
by Zacks Equity Research
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
pharmaceuticals
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
by Zacks Equity Research
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
VSTMNegative Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
by Zacks Equity Research
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
ENTXNegative Net Change BCYCPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.
SUPNPositive Net Change
medical pharmaceuticals
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
by Zacks Equity Research
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
HRTXPositive Net Change MRNSNegative Net Change IOVANegative Net Change ARQTNegative Net Change
biotechs medical pharmaceuticals